Sequence Bio announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio’s proprietary discovery platform to identify novel dermatologic drug targets.
| Multi-indication collaboration to focus on identification of novel therapeutic targets for dermatological applications ST. JOHN’S, NL, April 7, 2022 /PRNewswire/ - Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio’s proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insights generated under this collaboration to build robust evidence in support of new potential approaches that significantly impact dermatologic conditions.
“We are delighted to enter this collaboration agreement with Sequence Bio to further accelerate LEO Pharma’s ambition to identify novel dermatologic drug targets,” said Thorsten Thormann, Vice President of Research & Early Development in LEO Pharma. “LEO Pharma is relentlessly committed to making pioneering advances in dermatology research and bringing new treatments to patients faster.” “We are excited to work with LEO Pharma on their mission to positively impact millions of lives through medical dermatology,” said Dr. Richard Leach, Chief Strategy Officer of Sequence Bio. “This collaboration aligns with our strategic priorities to expand the potential of our discovery platform to power life-changing medicines in areas of unmet medical need across the globe.” About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of EUR 1,339 million. For more information, please visit www.LEO-Pharma.com About Sequence Bio Sequence Bio is a commercial-stage biotechnology company based in Newfoundland and Labrador, Canada. The company’s platform leverages Newfoundland’s founder effect to power discovery cohorts for novel target identification across numerous disease indications. Sequence Bio collaborates with the people of Newfoundland and Labrador, and partners with leading pharma and biotech to help accelerate the development of new medicines for global unmet medical need. For more information, please visit www.SequenceBio.com Media Contacts LEO Pharma: Henrik Heskjaer | +45 3140 6180 Sequence Bio: Adriann Kennedy | +1 800 296 3481 x745 Forward-Looking Statement The above information includes forward-looking statements related to our current expectations, plans, goals, strategic priorities, mission or assumptions, including but not limited to our future prospects and results, potential for additional collaborations or licensing arrangements, ability to perform and execute on our commitments, effect of trends in our industry, our financial and or operational results, and our financial or operational performance. Such forward-looking statements are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from the forward looking statements expressed or implied in such statements. Such forward-looking statements can, without limitation, be preceded by, followed by, or include words such as “believes”, “build”, “expects”, “anticipates”, “accelerate”, “estimates”, “expand”, “intends”, “plans”, “committed” or similar expressions, or may employ such future or conditional verbs as “may”, “will”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. Sequence Bio cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. These factors include, without limitation, risks related to: drug target discovery, therapeutic development, health outcomes, science our ability to enroll eligible participants; changes in law, regulations or interpretations and enforcement of regulatory guidance or changes in the financing environment or markets; our ability to obtain or protect intellectual property and commercialization rights; and the potential impact of COVID-19 on our business and finances. These forward-looking statements speak only as of the date of this press release and Sequence Bio assumes no duty to update such statements, whether expressed or implied.
SOURCE Sequence Bio |
View original content to download multimedia:
